Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 116.88 Million CNY | 121.85% |
| 2022 | 52.68 Million CNY | 193.14% |
| 2021 | 17.97 Million CNY | 42.78% |
| 2020 | 12.58 Million CNY | 86.02% |
| 2019 | 6.76 Million CNY | -25.29% |
| 2018 | 9.05 Million CNY | -56.87% |
| 2017 | 21 Million CNY | -56.25% |
| 2016 | 48 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 149.69 Million CNY | 28.07% |
| 2024 Q3 | 847.28 Million CNY | 116.33% |
| 2024 Q2 | 397.66 Million CNY | 165.65% |
| 2023 Q3 | 89.16 Million CNY | 47.64% |
| 2023 FY | 116.88 Million CNY | 121.85% |
| 2023 Q2 | 60.39 Million CNY | 6.59% |
| 2023 Q1 | 56.65 Million CNY | 7.54% |
| 2023 Q4 | 116.88 Million CNY | 31.09% |
| 2022 Q4 | 52.68 Million CNY | 122.3% |
| 2022 Q3 | 23.7 Million CNY | 5.75% |
| 2022 Q2 | 22.41 Million CNY | 6.95% |
| 2022 Q1 | 20.95 Million CNY | 16.59% |
| 2022 FY | 52.68 Million CNY | 193.14% |
| 2021 Q3 | 2.29 Million CNY | -48.14% |
| 2021 Q1 | 3.93 Million CNY | 0.0% |
| 2021 Q4 | 17.97 Million CNY | 682.3% |
| 2021 FY | 17.97 Million CNY | 42.78% |
| 2021 Q2 | 4.43 Million CNY | 12.72% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 FY | 12.58 Million CNY | 86.02% |
| 2020 Q3 | - CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 Q4 | - CNY | 0.0% |
| 2019 FY | 6.76 Million CNY | -25.29% |
| 2018 FY | 9.05 Million CNY | -56.87% |
| 2017 FY | 21 Million CNY | -56.25% |
| 2016 FY | 48 Million CNY | 0.0% |